Int. J. Sci. R. Tech., 2026 3(11)

Original Article

A Multidisciplinary peer-reviewed Journal
www.ijsrtjournal.com [ISSN: 2394-7063]

Recent Advances in Heterocyclic Compounds for Drug Discovery: Synthesis, Properties, and Applications

Synthetic and Computational Approaches to Heterocyclic Chemistry: Optimization and Drug Design

Dr. B. Sunitha*

Satavahana University College of Engineering, Husnabad, Telangana, India.

ABSTRACT

Heterocyclic compounds play a significant role in modern drug discovery because their structural diversity and tunable physicochemical properties support the development of therapeutic agents with diverse biological activities. These compounds contain one or more heteroatoms, such as nitrogen, oxygen, or sulfur, within their ring structures and are widely investigated for antimicrobial, anticancer, antiviral, antifungal, and other pharmacological applications. This review examines recent advances in heterocyclic compound synthesis, their physicochemical properties, biological applications, and significance in medicinal chemistry. Relevant literature published primarily between 2020 and 2025 was considered through a structured narrative review of research articles and reviews addressing heterocycle synthesis, structure–activity relationships (SAR), molecular optimization, and computational drug discovery. Particular attention is given to synthetic approaches, including multicomponent reactions, catalytic methods, microwave-assisted synthesis, mechanochemical techniques, and environmentally sustainable strategies. The review also discusses how substituent modification, bioisosteric replacement, molecular docking, quantitative structure–activity relationship modelling, and artificial intelligence can support lead identification and optimization. Despite substantial progress, challenges remain in improving selectivity, solubility, bioavailability, safety, synthetic scalability, and environmental sustainability. Overall, integrating innovative synthetic chemistry with computational modelling and experimental biological validation may accelerate the discovery of safer and more effective heterocyclic drug candidates.

Keywords: Heterocyclic compounds, drug discovery, medicinal chemistry, synthesis, structure–activity relationship, molecular optimization, computational drug design, green chemistry

INTRODUCTION

1.1 Background of Heterocyclic Compounds

Heterocyclic compounds are cyclic organic molecules containing at least one heteroatom, such as nitrogen (N), oxygen (O), or sulfur (S), within their ring structure. These compounds are classified according to ring size, heteroatom composition, and molecular architecture. Common examples include pyridine, imidazole, indole, furan, thiophene, quinoline, and thiazole. Their structural diversity and distinctive electronic properties make them important building blocks in pharmaceutical and medicinal chemistry. Heterocyclic scaffolds are frequently incorporated into drug molecules because they can influence molecular polarity, hydrogen bonding, solubility, and interactions with biological targets (Heravi & Zadsirjan, 2020; Pibiri, 2024).

1.2 Importance in Drug Discovery

Heterocyclic compounds contribute significantly to the development of therapeutic agents against bacterial, viral, fungal, inflammatory, and cancer-related diseases. Nitrogen-containing heterocycles, in particular, are widely represented in medicinal chemistry because their basicity and hydrogen-bonding characteristics can support interactions with enzymes, receptors, and other biological macromolecules. Oxygen- and sulfur-containing rings also provide opportunities to modify molecular reactivity, lipophilicity, and biological activity. Furthermore, heterocyclic scaffolds facilitate structural optimization, enabling researchers to investigate relationships

Relevant conflicts of interest/financial disclosures: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

between molecular structure and pharmacological performance (Hossain et al., 2024; Rusu et al., 2023).

1.3 Research Problem and Objectives

Despite considerable progress, developing effective heterocycle-based drugs remains challenging because of inadequate potency, poor selectivity, toxicity, limited aqueous solubility, and unfavorable pharmacokinetic properties. Conventional synthetic procedures may also involve hazardous reagents, costly catalysts, or inefficient purification steps. Therefore, integrating innovative synthesis techniques with physicochemical evaluation and biological testing is essential for improving drug discovery.

This review aims to examine recent advances in heterocyclic compound synthesis, evaluate their physicochemical properties, summarize their major therapeutic applications, and identify emerging research trends. It also discusses the challenges associated with molecular optimization and highlights future opportunities involving sustainable chemistry, computational drug design, and experimental validation.

2. Related Work

2.1 Classification of Heterocyclic Compounds

Heterocyclic compounds are classified according to their ring structure, heteroatom composition, and degree of saturation. Nitrogen-containing heterocycles, including pyridine, pyrimidine, imidazole, indole, and triazole, are widely investigated because of their diverse chemical properties and pharmaceutical relevance. Oxygen-containing heterocycles, such as furan and benzofuran, provide structural frameworks for developing bioactive molecules. Similarly, sulfur-containing heterocycles, including thiophene and thiazole, are important in medicinal chemistry. Fused heterocycles, such as quinoline and quinazoline, offer additional opportunities for molecular modification and target-specific drug design (Fig. 1.). Heravi and Zadsirjan (2020) highlighted the widespread presence of nitrogen heterocycles in prescribed drugs, demonstrating their importance in pharmaceutical development.




Figure 1: Representative Heterocyclic Ring Systems

Figure 1 illustrates six representative heterocyclic compounds: pyridine, imidazole, indole, quinoline, thiazole, and triazole. These structures contain nitrogen and/or sulfur atoms and serve as important scaffolds in medicinal chemistry and drug discovery.

2.2 Recent Advances in Heterocycle Synthesis

Recent advances in synthetic organic chemistry have expanded the methods available for preparing structurally diverse heterocyclic compounds. Multicomponent and one-pot reactions enable the construction of complex molecules through fewer reaction and purification steps. Transition-metal-catalyzed reactions facilitate selective bond formation and the functionalization of heterocyclic frameworks. Microwave-assisted synthesis can reduce reaction times in suitable chemical systems, whereas mechanochemical methods offer opportunities to minimize solvent consumption. Visible-light-mediated reactions have also attracted interest because they enable transformations under comparatively mild conditions. Sivaraj et al. (2025) reviewed emerging non-conventional approaches for synthesizing nitrogen-containing heterocycles, emphasizing their synthetic versatility. Mukherjee et al. (2025) examined advances in fluorinated heterocycle synthesis and their pharmaceutical relevance. Collectively, these developments support research into more efficient,

selective, and environmentally responsible synthetic strategies.

2.3 Therapeutic Applications

Heterocyclic scaffolds are investigated across several therapeutic areas. Nitrogen-containing rings are important in antimicrobial and antiviral drug research, while imidazole and triazole derivatives have significant applications in antifungal drug development. Quinoline and related fused heterocycles have been explored for antimalarial and antimicrobial activities. Indole, quinazoline, and other heterocyclic frameworks are also investigated in anticancer research, including the development of compounds targeting specific enzymes and cellular signalling pathways. In addition, heterocyclic derivatives have applications in anti-inflammatory research and the development of compounds targeting neurological disorders. Hossain et al. (2024) reviewed heterocyclic molecules used in cancer treatment, while Rusu et al. (2023) discussed the importance of five-membered heterocycles in antibacterial drugs. However, therapeutic activity depends on the complete molecular structure and must be established through appropriate biological testing.

2.4 Research Gap

Although previous studies have extensively examined heterocycle synthesis, molecular properties, and therapeutic activities, these aspects are not always integrated into a unified assessment of drug-discovery potential. Improvements in synthetic efficiency do not necessarily produce compounds with superior biological activity, safety, or pharmacokinetic characteristics. Similarly, promising computational predictions require experimental validation. Therefore, further research should connect sustainable synthesis, physicochemical characterization, structure–activity relationship analysis, and biological evaluation. This review addresses these interconnected dimensions and identifies opportunities to improve the safety, selectivity, scalability, and clinical translation of heterocycle-based drug candidates.

METHODOLOGY

3.1 Literature Search Strategy

A structured narrative literature review approach was adopted to examine recent advances in heterocyclic compounds for drug discovery. Relevant scientific literature was considered from PubMed, Scopus, Web of Science, ScienceDirect, and Google Scholar. The search focused primarily on publications from 2020 to 2025, while foundational studies were included where necessary to explain established concepts in medicinal chemistry and drug development. The review aimed to identify research addressing heterocyclic synthesis, physicochemical properties, biological activities, and pharmaceutical applications.

3.2 Search Keywords

The literature search used combinations of the following keywords: “heterocyclic compounds and drug discovery,” “heterocycle synthesis and medicinal chemistry,” “heterocyclic scaffolds and biological activity,” “green synthesis of heterocycles,” and “fluorinated heterocycles and pharmaceuticals.” Related terms covering antimicrobial agents, anticancer compounds, structure–activity relationships, and computational drug design were also considered to identify relevant research across different therapeutic areas.

3.3 Inclusion and Exclusion Criteria

Peer-reviewed research articles and review papers relevant to heterocyclic chemistry and pharmaceutical development were considered for inclusion. Priority was given to studies reporting synthetic procedures, structural characterization, physicochemical properties, biological assays, or drug-development applications. Foundational publications were retained when they provided essential information about established chemical principles. Duplicate publications, unrelated studies, and articles lacking sufficient methodological information were excluded from the review.

3.4 Data Extraction and Analysis

Relevant information was organized according to heterocyclic scaffold, synthesis method, physicochemical characteristics, reported biological activity, therapeutic application, and study limitations. The findings were compared qualitatively to identify recurring research trends, methodological advantages, and unresolved challenges. Particular attention was given to the relationship between molecular structure, synthetic efficiency, and pharmaceutical potential (Fig 2).




Figure 2: Heterocyclic Compound Drug-Discovery Workflow

Figure 2 illustrates the drug-discovery workflow, from molecular design and synthesis to characterization, biological screening, ADMET assessment, and lead optimization. The iterative process aims to improve the potency, selectivity, safety, and drug-like properties of heterocyclic compounds.

4. Results and Review Findings

4.1 Trends in Heterocycle Synthesis

The reviewed literature highlights growing interest in catalytic, one-pot, multicomponent, and sustainable methods for synthesizing heterocyclic compounds. Multicomponent reactions can produce structurally diverse molecules with fewer reaction steps, while transition-metal catalysis facilitates selective bond formation and functionalization. Microwave-assisted and mechanochemical techniques offer potential advantages in reaction time and solvent consumption, respectively. Visible-light-mediated synthesis also enables transformations under suitable photochemical conditions. However, their effectiveness depends on the substrate, reaction mechanism, catalyst, and scalability (Kushwaha et al., 2024; Sivaraj et al., 2025).

4.2 Physicochemical Properties

Physicochemical properties strongly influence the suitability of heterocyclic compounds for pharmaceutical development. Molecular weight, lipophilicity, aqueous solubility, membrane permeability, hydrogen-bonding capacity, and metabolic stability affect absorption, distribution, and interactions with biological targets. Introducing nitrogen, oxygen, or sulfur into a molecular ring can alter its electronic distribution and polarity. However, improvements in one property may adversely affect another.

The partition coefficient describes the distribution of a neutral compound between octanol and water:

$$\log P = \log_{10}\left(\frac{C_{octanol}}{C_{water}}\right)$$

Here, $C_{octanol}$ and C_{water} represent the equilibrium concentrations of the compound in the respective phases. Higher log*P* generally indicates greater lipophilicity, whereas lower values indicate greater preference for the aqueous phase. For ionizable compounds, the pH-dependent distribution coefficient, log D, is often more appropriate (Lipinski et al., 1997).

4.3 Biological and Pharmaceutical Applications

Heterocyclic scaffolds are investigated across diverse therapeutic areas. Their biological activity depends on the complete molecular structure, substituent positions, physicochemical characteristics, and interactions with biological targets.

Table 1: Representative Heterocyclic Scaffolds and Pharmaceutical Applications

Scaffold	Major application areas
Pyridine	Antimicrobial and targeted drug research
Imidazole	Antifungal and antimicrobial research
Indole	Anticancer and neurological research
Quinoline	Antimalarial and antimicrobial research
Thiazole	Antibacterial and anticancer research
Triazole	Antifungal and other therapeutic research

Source: Adapted conceptually from Heravi and Zadsirjan (2020), Hossain et al. (2024), and Rusu et al. (2023).

4.4 Comparison of Synthetic Methods

Table 2: Advantages and Limitations of Selected Heterocycle Synthesis Methods

Method	Potential advantage	Limitation
Multicomponent reactions	Structural diversity and fewer reaction steps	Competing reactions may occur
Metal catalysis	Selective bond formation	Catalyst cost and residual metals
Microwave synthesis	Potentially shorter reaction times	Scale-up and equipment constraints
Mechanochemistry	Potential reduction in solvent use	Reaction-dependent reproducibility
Photochemical synthesis	Access to alternative reaction pathways	Light penetration and catalyst requirements

Source: Qualitative synthesis of considerations discussed by Kushwaha et al. (2024) and Sivaraj et al. (2025).

Overall, the literature suggests that no single synthesis method is optimal for every heterocyclic scaffold. Method selection should consider reaction yield, selectivity, purity, safety, energy consumption, and scalability. Likewise, pharmaceutical potential must be assessed through physicochemical characterization and biological validation rather than inferred from the presence of a particular heterocyclic ring alone.

DISCUSSION

5.1 Structure–Activity Relationships

Structure–activity relationship (SAR) analysis is essential for understanding how chemical modifications influence the biological activity of heterocyclic compounds. Ring size, heteroatom position, aromaticity, and substituent distribution can affect molecular conformation, electronic properties, and interactions with biological targets. Substituents may improve binding affinity or selectivity, but their effects depend on the target and the surrounding molecular structure. Therefore, systematic structural modification and biological testing are necessary to identify promising drug candidates (Heravi & Zadsirjan, 2020; Rusu et al., 2023).

5.2 Molecular Optimization

Molecular optimization aims to improve potency, selectivity, solubility, permeability, and metabolic stability. Fluorination can modify molecular lipophilicity, acidity, and susceptibility to metabolic transformation, although these effects are structure-dependent. Bioisosteric replacement provides another strategy for modifying molecular properties while retaining important biological interactions. Such approaches should be evaluated using experimental measurements rather than assuming that a particular substitution will necessarily improve pharmaceutical performance (Mukherjee et al., 2025; Subbaiah & Meanwell, 2021).




Figure 3: Structure Activity Relationship (SAR) and Molecular Optimization of Heterocyclic Compounds.

Figure 3 illustrates how structural modifications to a heterocyclic compound can influence biological activity and support lead optimization. Changes in substituent groups and molecular interactions may improve potency, selectivity, and drug-like properties during drug discovery.

5.3 Computational Drug Discovery

Computational approaches increasingly support heterocycle-based drug discovery. Molecular docking estimates potential ligand–target binding poses, while molecular dynamics simulations investigate the behavior and stability of molecular complexes over time. Quantitative structure–activity relationship (QSAR) models identify associations between molecular descriptors and biological activity. Artificial intelligence and machine learning can further assist compound screening and prioritization. Nevertheless, predictions depend on data quality, model validation, and the applicability of the training data to new compounds. Computational findings should therefore be confirmed through appropriate experimental studies.

5.4 Challenges and Limitations

Several challenges continue to restrict the development of heterocyclic drug candidates. Unwanted toxicity and off-target effects can limit therapeutic usefulness, while antimicrobial resistance complicates the development of effective anti-infective agents. Poor aqueous solubility, inadequate permeability, and unfavorable metabolic stability can also reduce bioavailability. In addition, costly catalysts, hazardous reagents, complex purification, and difficulties in scaling laboratory procedures may affect manufacturing feasibility. Importantly, strong in-vitro activity does not guarantee clinical efficacy because drug performance also depends on pharmacokinetics, safety, dosage, and biological complexity.

5.5 Research Implications

Future research should integrate computational predictions with synthesis, structural characterization, biological assays, and pharmacokinetic evaluation. Researchers should also develop reproducible synthetic protocols that document reaction conditions, yields, purity, and environmental considerations. Combining molecular optimization with sustainable chemistry and rigorous experimental validation may improve the identification of safer, more selective, and developable heterocyclic drug candidates.

6. Conclusion and Future Work

6.1 Conclusion

Heterocyclic compounds play a significant role in modern drug discovery because their structural diversity and physicochemical properties support the development of therapeutically relevant molecules. Nitrogen-, oxygen-, and sulfur-containing scaffolds are widely investigated for antibacterial, antiviral, antifungal, anticancer, and anti-inflammatory applications. Advances in catalytic reactions, multicomponent synthesis, fluorination, and sustainable chemistry have expanded the possibilities for preparing and modifying heterocyclic structures. Furthermore, structure–activity relationship analysis and computational methods support the optimization of molecular potency, selectivity, and drug-like properties. However, toxicity, poor solubility, antimicrobial resistance, and limitations in translating laboratory findings into clinical outcomes remain important challenges.

6.2 Future Work

Future research should prioritize environmentally sustainable and scalable synthesis methods that reduce hazardous reagents, solvent consumption, and energy requirements. Artificial intelligence and machine learning may accelerate molecular design and candidate selection when supported by reliable data and rigorous validation. Further investigation is also needed to improve safety, bioavailability, metabolic stability, and target selectivity. Predicted biological activities should be confirmed through reproducible laboratory experiments, followed by appropriate pharmacokinetic and toxicological evaluations. Integrating medicinal chemistry, computational modelling, pharmacology, and pharmaceutical development will be essential for translating promising heterocyclic compounds into effective and safe therapeutic agents.

REFERENCES

1. Bansal, N., Dadwal, A., & Kumar, B. (2025). Key heterocyclic moieties for the next five years of drug discovery and development. Future Medicinal Chemistry, 17 (22), 2657–2659. https://doi.org/10.1080/17568919.2025.2575747
2. Ballatore, C., Huryn, D. M., & Smith, A. B., III. (2013). Carboxylic acid (bio)isosteres in drug design. ChemMedChem, 8 (3), 385–395. https://doi.org/10.1002/cmdc.201200585
3. Chowdhury, M. G., Kalmegh, V., Kapoor, S., Kamble, V., & Shard, A. (2024). Imidazopyrimidine: From a relatively exotic scaffold to an evolving structural motif in drug discovery. RSC Medicinal Chemistry. https://doi.org/10.1039/D3MD00718A
4. Heravi, M. M., & Zadsirjan, V. (2020). Prescribed drugs containing nitrogen heterocycles: An overview. RSC Advances, 10, 44247–44311. https://doi.org/10.1039/D0RA09198G
5. Hossain, M., Habib, I., Singha, K., & Kumar, A. (2024). FDA-approved heterocyclic molecules for cancer treatment: Synthesis, dosage, mechanism of action and their adverse effect. Heliyon, 10 (1), Article e23172. https://doi.org/10.1016/j.heliyon.2023.e23172
6. Jampilek, J. (2024). Heterocycles in medicinal chemistry II. Molecules, 29 (20), Article 4810. https://doi.org/10.3390/molecules29204810
7. Kabir, E., & Uzzaman, M. (2022). A review on biological and medicinal impact of heterocyclic compounds. Results in Chemistry, 4, Article 100606. https://doi.org/10.1016/j.rechem.2022.100606
8. Karthikeyan, S., Grishina, M., Kandasamy, S., Mangaiyarkarasi, R., Ramamoorthi, A., Chinnathambi, S., Pandian, G. N., & Kennedy, L. J. (2023). A review on medicinally important heterocyclic compounds and importance of biophysical approach of underlying the insight mechanism in biological environment. Journal of Biomolecular Structure and Dynamics, 41 (23), 14599–14619. https://doi.org/10.1080/07391102.2023.2187640
9. Khan, K., Ali, R., Khatoon, S., Khan, A., Kumar, P., Ahamad, S., Saquib, M., & Hussain, M. K. (2025). The Groebke–Blackburn–Bienaymé (GBB) reaction: A powerful tool for generating diverse heterocyclic scaffold libraries in anticancer drug discovery. European Journal of Medicinal Chemistry, 291, Article 117629. https://doi.org/10.1016/j.ejmech.2025.117629
10. Khator, R., & Monga, V. (2025). Thiazolopyrimidine, a privileged scaffold: Recent updates on synthetic and pharmacological perspective in drug discovery. Archiv der Pharmazie, 358 (3), Article e2400870. https://doi.org/10.1002/ardp.202400870
11. Kushwaha, P., Rashi, Bhardwaj, A., & Khan, D. (2024). Synthetic approaches toward imidazo-fused heterocycles: A comprehensive review. Journal of Heterocyclic Chemistry, 61 (11), 1807–1869. https://doi.org/10.1002/jhet.4910
12. Lipinski, C. A., Lombardo, F., Dominy, B. W., & Feeney, P. J. (1997). Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Advanced Drug Delivery Reviews, 23 (1–3), 3–25. https://doi.org/10.1016/S0169-409X (96)00423-1
13. Lipinski, C. A. (2016). Rule of five in 2015 and beyond: Target and ligand structural limitations, ligand chemistry structure and drug discovery project decisions. Advanced Drug Delivery Reviews, 101, 34–41. https://doi.org/10.1016/j.addr.2016.04.029
14. Luo, W., Liu, Y., Qin, H., Zhao, Z., Wang, S., He, W., Tang, S., & Peng, J. (2024). Nitrogen-containing heterocyclic drug products approved by the FDA in 2023: Synthesis and biological activity. European Journal of Medicinal Chemistry, 279, Article 116838. https://doi.org/10.1016/j.ejmech.2024.116838
15. Mandal, S., Jain, A., & Panda, T. K. (2025). A facile route to access N-heterocycles using a choline chloride–ethylene glycol-based DES in a dual role. Organic & Biomolecular Chemistry, 23, 8788–8795. https://doi.org/10.1039/D5OB01090J
16. Meanwell, N. A. (2011). Synopsis of some recent tactical application of bioisosteres in drug design. Journal of Medicinal Chemistry, 54 (8), 2529–2591. https://doi.org/10.1021/jm1013693
17. Mukherjee, S., Rani, U., Chandra, G., & Pal, S. (2025). Recent advances in the synthesis of fluorinated heterocycles and a review of recent

FDA-approved fluorinated drugs. Organic & Biomolecular Chemistry, 23, 7821–7851. https://doi.org/10.1039/D5OB00997A

18. Nguyen, H. T., Nguyen, T. T., Doan, V. T. C., Nguyen, T. H., & Tran, M. H. (2025). Recent advances in metal-free catalysts for the synthesis of N-heterocyclic frameworks focusing on 5- and 6-membered rings: A review. RSC Advances, 15, 9676–9755. https://doi.org/10.1039/D5RA00962F
19. Pibiri, I. (2024). Recent advances: Heterocycles in drugs and drug discovery. International Journal of Molecular Sciences, 25 (17), Article 9503. https://doi.org/10.3390/ijms25179503
20. Rusu, A., Moga, I.-M., Uncu, L., & Hancu, G. (2023). The role of five-membered heterocycles in the molecular structure of antibacterial drugs used in therapy. Pharmaceutics, 15 (11), Article 2554. https://doi.org/10.3390/pharmaceutics15112554
21. Sivaraj, N., Sakthivel, K., Kikushima, K., Kostić, M. D., Dohi, T., & Singh, F. V. (2025). Recent advances in non-conventional synthesis of N-heterocyclic compounds: Emerging strategies and biological perspectives. RSC Advances, 15, 35509–35531. https://doi.org/10.1039/D5RA06028A
22. Subbaiah, M. A. M., & Meanwell, N. A. (2021). Bioisosteres of the phenyl ring: Recent strategic applications in lead optimization and drug design. Journal of Medicinal Chemistry, 64 (19), 14046–14128. https://doi.org/10.1021/acs.jmedchem.1c01215
23. Wal, P., Wal, A., Jawaid, T., Ganguly, P., Patel, B., Nainwal, P., Lari, M. Q., Kumar, A., & Kumar, D. (2025). Crossing boundaries: A review of the diverse functions of heterocyclic compounds in the management of cancer and infectious diseases. Current Drug Targets, 26 (12), 850–866. https://doi.org/10.2174/0113894501372336250703114127
24. Zhdankin, V. V. (2024). Organohypervalent heterocycles. Chemical Society Reviews, 53 (9), 4786–4827. https://doi.org/10.1039/D2CS01055K
25. Lovering, F., Bikker, J., & Humblet, C. (2009). Escape from flatland: Increasing saturation as an approach to improving clinical success. Journal of Medicinal Chemistry, 52 (21), 6752–6756. https://doi.org/10.1021/jm901241e
26. Quin, L. D., & Tyrell, J. A. (2010). Fundamentals of heterocyclic chemistry: Importance in nature and in the synthesis of pharmaceuticals. Wiley.
27. Nadar, S., Borkar, M., & Khan, T. (2025). Thienopyrimidine: Unveiling the versatile potential of a promising heterocyclic scaffold in drug discovery. Chemical Biology & Drug Design, 105 (6), Article e70146. https://doi.org/10.1111/cbdd.70146
28. Khan, Y., Sarfraz, H., Rehman, W., Khan, M., Rasheed, L., & Rahman, K. U. (2025). Innovative horizons in drug design: Exploring the synthesis and medicinal properties of heterocyclic Schiff bases. A review. Mini Reviews in Medicinal Chemistry, 25 (10), 727–744. https://doi.org/10.2174/0113895575320413250126041041
29. Rácz, A., Mihalovits, L. M., Beckers, M., et al. (2025). The changing landscape of medicinal chemistry optimization. Nature Reviews Drug Discovery, 24, 870–887. https://doi.org/10.1038/s41573-025-01225-1
30. Bansal, N., Dadwal, A., & Kumar, B. (2025). Key heterocyclic moieties for the next five years of drug discovery and development. Future Medicinal Chemistry, 17 (22), 2657–2659. https://doi.org/10.1080/17568919.2025.2575747

HOW TO CITE: Dr. *B. Sunitha*, Recent Advances in Heterocyclic Compounds for Drug Discovery: Synthesis, Properties, and Applications

Synthetic and Computational Approaches to Heterocyclic Chemistry: Optimization and Drug Design, Int. J. Sci. R. Tech., 2026, 3 (11), 381-388. https://doi.org/10.5281/zenodo.23976133